Skip NavigationSkip to Content

Novel primary amine diazeniumdiolates-Chemical and biological characterization

  1. Author:
    Puglisi, Melany P [ORCID]
    Bradaric, Michael J [ORCID]
    Pontikis, John
    Cabai, Jonathan
    Weyna, Theodore
    Tednes, Patrick
    Schretzman, Robert
    Rickert, Karl
    Cao, Zhao
    Andrei, Daniela [ORCID]
  2. Author Address

    Department of Pharmaceutical Sciences, Chicago State University, Chicago, Illinois., Department of Chemistry, Dominican University, River Forest, Illinois., Basic Research Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.,
    1. Year: 2018
    2. Date: May 02
    3. Epub Date: 2018 05 02
  1. Journal: Drug development research
  2. Type of Article: Article
  1. Abstract:

    Hit, Lead & Candidate Discovery Diazeniumdiolates, also known as NONOates, are extensively used in biochemical, physiological, and pharmacological studies due to their ability to release nitric oxide (NO. ) and/or their congeneric nitroxyl (HNO). The purpose of this work was to synthesize a series of primary amine-based diazeniumdiolates as HNO/NO donors and to determine their efficacy as anticancer and antifungal agents in vivo. The seven compounds (3a-3g) were successfully synthesized and characterized, one of which had been previously reported in the literature (3g). Two compounds showed anti-proliferative effects against ovarian (ES2 and SKOV3) and AML monocyte-derived cancer cells (THP-1) when tested with standard MTT assays. Compounds 3a and 3g demonstrated reduced ovarian cancer cell proliferation when treated at doses from 0.033 to 1.0 mg/mL at the 24 hr time point. These compounds also exhibited moderate and selective antifungal activity against Fusarium oxysporum f.sp. lycopersici, one cause of opportunistic infections of immunocompromised patients, inhibiting the growth of the fungi at LD50 at 10 mg/mL. A third compound (3e) did not exhibit similar activities, possibly due to the alkyl chain. Our results suggest that the primary amine diazeniumdiolates may offer a versatile platform for the development of HNO/NO donors for biomedical applications. © 2018 Wiley Periodicals, Inc.

    See More

External Sources

  1. DOI: 10.1002/ddr.21428
  2. PMID: 29719056

Library Notes

  1. Fiscal Year: FY2017-2018
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel